Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Merck & Co stands fully behind Vytorin

This article was originally published in Scrip

Executive Summary

You may also be interested in...



Stay Or Exit? Global Health Players Ponder New China Trajectory

It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.

Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'

A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net. 

Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign

Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC000665

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel